Trials / Completed
CompletedNCT05841940
Mass Balance Study of [14C]HLX208 in China Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Shanghai Henlius Biotech · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Mass Balance Study of \[14C\]HLX208 in China Healthy Subjects.
Detailed description
A phase I study to quantify the total mass balance in healthy subjects after a single dose of \[14C\]HLX208.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]HLX208 | Carbon-14 labeled HLX208 |
Timeline
- Start date
- 2023-06-17
- Primary completion
- 2023-07-15
- Completion
- 2023-12-15
- First posted
- 2023-05-03
- Last updated
- 2024-01-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05841940. Inclusion in this directory is not an endorsement.